Literature DB >> 15354204

Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study.

M Díez-Campelo1, J A Pérez-Simón, J R González-Porras, J M García-Cecilia, M Salinero, M D Caballero, M C Cañizo, E M Ocio, J F San Miguel.   

Abstract

The aim was to analyze quality-of-life (QOL) during the first year post transplant in 47 patients undergoing reduced-intensity conditioning (RIC) allotransplantation, and to compare these with a similar subgroup of patients receiving autologous stem cell transplantation (ASCT). We used self-reported questionnaires. Each answer scored from 0 (not at all) to 4 (very much), with higher scores indicating worse functioning. Mean value of physical categories among RIC transplants ranged between 1.23 and 0.77 indicating that patients scored very low for physical symptoms. Patients undergoing ASCT had higher scores in questionnaires performed early after transplant and then gradually improved (P < 0.001). Overall, when we compared physical functioning scores, allo-RIC did significantly better (P = 0.049). Nevertheless, while allo-RIC scores were significantly better for the first three questionnaires, ASCT patients did better in the last two questionnaires. These findings are in accordance with the toxicities observed in both subgroups which are lower in the RIC group early after transplant. No significant differences were observed between either subgroup for any of the functional, social/ family, psychological distress and satisfaction with doctor/nurse relationship items. We have observed similar QOL among patients undergoing RIC-allo as compared to ASCT although GVHD remains an important 'event' in QOL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15354204     DOI: 10.1038/sj.bmt.1704646

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  19 in total

1.  Quality of Life after Autologous Peripheral Blood Stem Cell Transplantation and High-Dose Chemotherapy in High-Risk Breast Cancer Patients.

Authors:  Li Zhang; Zhongsheng Tong; Shufen Li; Xiubao Ren; Baozhu Ren; Xu Wang; Shui Cao; Chen Wang; Lihong He
Journal:  Breast Care (Basel)       Date:  2009-12-28       Impact factor: 2.860

Review 2.  Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature.

Authors:  Catherine E Mosher; William H Redd; Christine M Rini; Jack E Burkhalter; Katherine N DuHamel
Journal:  Psychooncology       Date:  2009-02       Impact factor: 3.894

Review 3.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

Review 4.  Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical management.

Authors:  Heather S L Jim; Bryan Evans; Jiyeon M Jeong; Brian D Gonzalez; Laura Johnston; Ashley M Nelson; Shelli Kesler; Kristin M Phillips; Anna Barata; Joseph Pidala; Oxana Palesh
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-18       Impact factor: 5.742

5.  Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study.

Authors:  Matthias Naegele; Monika Kirsch; Gabriele Ihorst; Katharina Fierz; Monika Engelhardt; Sabina De Geest
Journal:  Support Care Cancer       Date:  2017-09-16       Impact factor: 3.603

6.  Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study.

Authors:  Peter Esser; Katharina Kuba; Angela Scherwath; Lena Schirmer; Frank Schulz-Kindermann; Andreas Dinkel; Friedrich Balck; Uwe Koch; Nicolaus Kröger; Heide Götze; Anja Mehnert
Journal:  J Cancer Surviv       Date:  2016-10-31       Impact factor: 4.442

Review 7.  Chronic graft-versus-host disease: Pathogenesis and clinical management.

Authors:  José A Pérez-Simón; Ignacio Sánchez-Abarca; María Díez-Campelo; Dolores Caballero; Jesús San Miguel
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia.

Authors:  S Kurosawa; T Yamaguchi; T Mori; H Kanamori; Y Onishi; N Emi; S Fujisawa; A Kohno; C Nakaseko; B Saito; T Kondo; M Hino; Y Nawa; S Kato; A Hashimoto; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2015-06-15       Impact factor: 5.483

9.  Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902 Data.

Authors:  Heather S L Jim; Steven K Sutton; Brent J Small; Paul B Jacobsen; William A Wood; Jennifer M Knight; Navneet S Majhail; Karen L Syrjala; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-15       Impact factor: 5.742

10.  Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation.

Authors:  Areej R El-Jawahri; Harry B Vandusen; Lara N Traeger; Joel N Fishbein; Tanya Keenan; Emily R Gallagher; Joseph A Greer; William F Pirl; Vicki A Jackson; Thomas R Spitzer; Yi-Bin A Chen; Jennifer S Temel
Journal:  Cancer       Date:  2015-12-09       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.